This is a the United States news story, published by Yahoo.
For more the United States news, you can click here:
more the United States newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Yahoo, you can click here:
more news from YahooOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
synovial sarcoma. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest prior chemotherapy news, kind gene therapy news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
first gene therapyReuters
•79% Informative
Adaptimmune 's first -of-its-kind gene therapy approved to treat a rare type of cancer in the soft tissues.
Synovial sarcoma typically affects young men and impacts about 1,000 people in the United States each year .
The company said the treatment would launch at a list price of $ 727,000 .
VR Score
88
Informative language
93
Neutral language
61
Article tone
formal
Language
English
Language complexity
57
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links